References
- Gelmon K. The taxoids: Paclitaxel and docetaxel. Lancet 1994; 344: 1267–72
- Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, van Odsterom A, et al. Coping with the toxicities of docetaxel (Taxotere). Ann Oncol 1993; 4: 610–1
- Semb KA, Aamdal S, Øian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998; 16: 3426–32
- Brønstad A, Berg A, Reed RK. Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol 2004; 287: H963–H968
- Kataoka, K, Taniguchi, H, Hasegawa, Y, Kondoh, Y, Knonura, T, Nishiyama, O, et al. Interstitial lung disease associated with gefitinib. Respir Med 2005;29, (Epub).
- Anthony VB, Godbey SW, Kunkel SL, Hott JW, Hartman DL, Burdick MD, et al. Recruitment of inflammatory cells to the pleural space: Chemotactic cytokines, IL-8, and monocyte chemotactic peptide-1 in human pleural fluids. J Immunol 1993; 151: 7216–33
- Pace E, Gjomarkaj M, Melis M, Profita M, Spatafora M, Vignola AM, et al. Interleukin-8 induces lymphocyte chemotaxis into the pleural space: Role of pleural macrophages. Am J Respir Crit Care Med 1999; 159: 1592–9
- Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54: 721–8
- Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444–51
- Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improves survival in lung cancer: Documentation and analysis of a natural experiment. N Engl J Med 1972; 287: 1013–7
- Wei YQ, Hang ZB. In situ observation of lymphocyte-tumor cell interaction in human lung carcinoma. Immunol Invest 1989; 18: 1095–105